Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$315K Sell
11,040
-372
-3% -$9.9K 0.23% 82
2026
Q2
$275K Hold
11,412
– – 0.21% 88
2026
Q1
$320K Hold
11,412
– – 0.26% 77
2025
Q4
$284K Hold
11,412
– – 0.22% 84
2025
Q3
$291K Sell
11,412
-612
-5% -$15.1K 0.22% 85
2025
Q2
$291K Sell
12,024
-340
-3% -$7.93K 0.23% 86
2025
Q1
$313K Sell
12,364
-889
-7% -$23.3K 0.27% 81
2024
Q4
$352K Buy
+13,253
New +$359K 0.3% 76

Other funds holding PFE

Finward Bancorp's PFE Position: Q3 2026 in Review

Finward Bancorp reduced its Pfizer (PFE) stake by 3.3% in Q3 2026, selling an estimated $9.9K and leaving 11,040 shares worth $315K. The position accounts for 0.23% of the portfolio, ranked #82.

Finward Bancorp first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. The position peaked at $352K in Q4 2024. 648 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Finward Bancorp held 11,040 shares of Pfizer worth $315K as of Q3 2026.
  • Finward Bancorp sold 372 Pfizer shares in Q3 2026, an estimated $9.9K.
  • Pfizer made up 0.23% of Finward Bancorp's portfolio in Q3 2026, its #82 holding.
  • Finward Bancorp first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • Finward Bancorp's Pfizer position peaked at $352K in Q4 2024.
  • 648 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Finward Bancorp's 13F filing for Q3 2026, filed 14 Oct 2026.